Phase I Combination Ixabepilone + Cisplatin

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Ixabepilone

Escalation: Solution, intravenous (IV), 32-40 mg/m2, every 3 weeks, approximately 6 months

DRUG

Cisplatin

Escalation: Solution, IV, 60-100 mg/m2, every 3 weeks, approximately 6 months

DRUG

Ixabepilone

Expansion: Solution, IV, 32 mg/m2, every 3 weeks, approximately 6 months

DRUG

Cisplatin

Expansion: Solution, IV, 60-80 mg/m2, every 3 weeks, approximately 6 months

Trial Locations (7)

17033

Penn State Milton S. Hershey Medical Center, Hershey

20007

Georgetown University Medical Center, Washington D.C.

47014

Local Institution, Meldola (Fc)

47900

Local Institution, Rimini

55100

Local Institution, Lucca

08901

The Cancer Institute Of New Jersey, New Brunswick

01100

Local Institution, Viterbo

Sponsors

Lead Sponsor

All Listed Sponsors
lead

R-Pharm

INDUSTRY